Article
Oncology
Takaaki Fujimura, Yoriko Yamashita-Kashima, Natsumi Kawasaki, Shigeki Yoshiura, Naoki Harada, Yasushi Yoshimura
Summary: Retreatment with obinutuzumab in combination with chemotherapeutic agents is effective in CD20-positive obinutuzumab-induced direct-cell-death-resistant cells, showing significant antitumor effects in mouse xenograft models.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Oncology
Stephanie Durand-Panteix, Jacques Monteil, Magali Sage, Armand Garot, Marie Clavel, Amal Saidi, Julien Torgue, Michel Cogne, Isabelle Quelven
Summary: This study investigated the potential of alpha-RIT in combination with Pb-212-rituximab for NHL treatment using mouse lymphoma cells. Results showed significant tumor regression and increased survival using 277.5 kBq Pb-212-rituximab, highlighting the potency of alpha-RIT for NHL treatment.
BRITISH JOURNAL OF CANCER
(2021)
Review
Oncology
Stephen Jolles, Sergio Giralt, Tessa Kerre, Hillard M. Lazarus, S. Shahzad Mustafa, Roberto Ria, Donald C. Vinh
Summary: This study conducted a systematic literature review on the potential association between various cancer regimens and infection rates, neutropenia, lymphocytopenia, or hypogammaglobulinemia, which are indicative of secondary immunodeficiency. The results showed that patients with chronic lymphocytic leukemia, multiple myeloma, and non-Hodgkin lymphoma have a high risk of developing secondary immunodeficiency, related infections, and mortality.
FRONTIERS IN ONCOLOGY
(2023)
Review
Hematology
Stephen Jolles, Sergio Giralt, Tessa Kerre, Hillard M. Lazarus, S. Shahzad Mustafa, Genovefa A. Papanicolaou, Marcel Reiser, Roberto Ria, Donald C. Vinh, John R. Wingard
Summary: Lymphoid hematologic malignancies and their treatment can lead to secondary antibody deficiency (SAD), increasing the risk of severe infections. In order to manage patients with these malignancies effectively, it is crucial to recognize and diagnose SAD and provide appropriate treatment. This consensus review from international experts aims to raise awareness about SAD and offer practical recommendations for its diagnosis and management. It emphasizes the importance of proactive and individualized patient management to reduce infection risk and improve outcomes.
Review
Medicine, General & Internal
Matteo D'Addona, Valentina Giudice, Luca Pezzullo, Giuseppe Ciancia, Carlo Baldi, Marisa Gorrese, Angela Bertolini, Annapaola Campana, Lucia Fresolone, Paola Manzo, Pio Zeppa, Bianca Serio, Carmine Selleri
Summary: Richter's syndrome is a pathological transformation of CLL into more aggressive diseases, most commonly diffuse large B-cell lymphoma. This study describes two rare cases of Richter's syndrome and discusses the increased risk associated with novel targeted therapies.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Andres Chang, Akil Akhtar, Susanne L. Linderman, Lilin Lai, Victor M. Orellana-Noia, Rajesh Valanparambil, Hasan Ahmed, Veronika Zarnitsyna, Ashley A. McCook-Veal, Jeffrey M. Switchenko, Jean L. Koff, Kristie A. Blum, Amy A. Ayers, Colin B. O'Leary, Michael C. Churnetski, Shahana Sulaiman, Melissa Kives, Preston Sheng, Carl W. Davis, Ajay K. Nooka, Rustom Antia, Madhav Dhodapkar, Mehul S. Suthar, Jonathon B. Cohen, Rafi Ahmed
Summary: Patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia have lower antibody responses to SARS-CoV-2 vaccines, particularly in those treated with anti-CD20 therapy or with low B-cell counts.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Hematology
Shazia Nakhoda, Aldana Vistarop, Y. Lynn Wang
Summary: Bruton tyrosine kinase inhibitors (BTKi) have had a significant impact on the treatment of chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma. However, resistance to BTKi remains a challenge, and this review article provides an update on the key clinical data, mechanisms of resistance, and ongoing clinical investigations in CLL, mantle cell lymphoma, and diffuse large B-cell lymphoma (DLBCL).
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Pathology
Akiko Miyagi Maeshima, Hirokazu Taniguchi, Daiki Hattori, Hirokazu Sasaki, Yoshikazu Hori, Shinichi Makita, Noriko Iwaki, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Koji Izutsu
Summary: Histopathological diagnoses of rare CD3- and CD20-negative extramedullary leukemias/lymphomas are challenging. In this study, 118 cases of CD3- CD20- extramedullary leukemias/lymphomas were reported, with anaplastic large cell lymphoma being the most common (41%), followed by large B-cell lymphoma/plasmablastic lymphoma (30%).
Article
Immunology
Federica Calo, Lorenzo Onorato, Mariantonietta Pisaturo, Antonio Pinto, Loredana Alessio, Caterina Monari, Carmine Minichini, Manuela Arcamone, Alessandra Di Fraia, Luigi Atripaldi, Claudia Tiberio, Nicola Coppola
Summary: There is limited data regarding the effectiveness of anti-SARS-CoV-2 vaccine in immunocompromised patients. This report presents the virological and clinical characteristics of a patient with follicle center lymphoma who was infected by the SARS-CoV-2 Omicron variant despite receiving three doses of the BNT162b2 vaccine. The patient initially experienced remission due to early therapy with sotrovimab, but suffered a fatal relapse caused by the same viral strain.
Article
Oncology
Francesco Maria Adamo, Estevao Carlos Silva Barcelos, Filomena De Falco, Erica Dorillo, Chiara Rompietti, Daniele Sorcini, Arianna Stella, Beatrice Del Papa, Stefano Baldoni, Angela Esposito, Clelia Geraci, Roberta Arcaleni, Chiara Pennetta, Francesco Ragonese, Lorenzo Moretti, Mariagrazia Mameli, Mauro Di Ianni, Emanuela Rosati, Bernard Fioretti, Paolo Sportoletti
Summary: In this study, the cytotoxicity of silver nanoparticles (AgNPs) against chronic lymphocytic leukemia (CLL) cells was highlighted, and the synergistic activity of AgNPs with drugs currently used in CLL, such as Venetoclax and Ibrutinib, was demonstrated. The conjugation of AgNPs with the anti-CD20 antibody Rituximab (AgNPs@Rituximab) increased the specificity and cytotoxicity of AgNPs toward CLL cells in vitro. AgNPs@Rituximab also extended the survival of CLL xenograft models compared to each unconjugated single agent.
Article
Hematology
Kai Zhu, Andrew Jamroz, Steven Huang, Diego Villa, Ciara L. Freeman, David W. Scott, Graham Slack, Laurie H. Sehn, Joseph M. Connors, Cynthia L. Toze, Kerry J. Savage, Alina S. Gerrie
Summary: Hodgkin variant Richter transformation (HvRT) is a rare and challenging complication of chronic lymphocytic leukaemia (CLL) with limited information on prognostic factors and treatment approaches. In a population-based cohort from British Columbia, poor clinical outcomes were observed in the majority of HvRT patients, although those who received curative-intent therapy had similar survival rates to older patients with de novo Hodgkin lymphoma.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Christine E. Ryan, Danielle M. Brander, Paul M. Barr, Svitlana Tyekucheva, Liam R. Hackett, Mary C. Collins, Stacey M. Fernandes, Yue Ren, Yinglu Zhou, Mikaela M. McDonough, Heather A. Walker, Monica R. McEwan, Jeremy S. Abramson, Eric D. Jacobsen, Ann S. LaCasce, David C. Fisher, Jennifer R. Brown, Matthew S. Davids
Summary: This study examined the use of ibrutinib plus obinutuzumab in relapsed/refractory CLL, assessing tolerability of different sequencing regimens and overall safety and efficacy. The results showed that the combination therapy was highly effective, with a manageable safety profile. The study supports further investigation of this approach in treating relapsed/refractory CLL.
Article
Medicine, General & Internal
Tinera Buckley, Arati Inamdar, Nagyl H. Mikhail, Abraham Loo, Seth Cohen
Summary: This case report highlights a rare transformation of CLL to Hodgkin lymphoma Richter transformation, emphasizing the diagnostic challenges and pitfalls associated with the granulomatous presentation.
AMERICAN JOURNAL OF CASE REPORTS
(2021)
Letter
Oncology
Alberto Fresa, Francesco Autore, Idanna Innocenti, Alfonso Piciocchi, Annamaria Tomasso, Francesca Morelli, Federica Sora, Simona Sica, Valerio De Stefano, Luca Laurenti
Summary: Infusion-related reactions are a common complication of obinutuzumab administration, with subclinical coagulopathy observed in some patients after the first infusion. Differences in platelet count were significant between patients with and without non-overt DIC, suggesting a potential relationship with platelet consumption post-lysis of lymphocytes. Further research is needed to better understand the pathogenesis of this adverse event.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Immunology
Yu-Chen Enya Chen, Melinda Burgess, Sally Mapp, Peter Mollee, Devinder Gill, Antje Blumenthal, Nicholas A. Saunders
Summary: The study reveals that the SIRP alpha axis suppresses ADP responses to the anti-CD20 antibody by NLCs derived from CLL patients, and further demonstrates that this innate immune checkpoint contributes to resistance through the regulation of the Shp1-mediated pathway.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Richard C. Walshaw, Jamie Honeychurch, Ananya Choudhury, Timothy M. Illidge
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2020)
Review
Oncology
Erminia Romano, Jamie Honeychurch, Timothy M. Illidge
Summary: Radiotherapy (RT) is highly effective at killing tumor cells and has additional immunomodulatory properties that can potentially improve its efficacy and cancer outcomes when combined with immunotherapy. Combining RT with immunomodulatory agents aims to enhance anti-tumor immune responses and improve treatment responses and patient outcomes. Important questions need to be addressed for effective clinical translation of RT and immunotherapy combinations, including optimal RT dose, target volume, choice of immuno-oncology agents, administration routes, and schedules.
Article
Oncology
Peter Hoskin, Biliana Popova, Oliver Schofield, Caroline Brammer, Martin Robinson, A. Murray Brunt, Krishnaswamy Madhavan, Tim Illidge, Eve Gallop-Evans, Isabel Syndikus, Laura Clifton-Hadley, Amy A. Kirkwood
Summary: The FoRT trial compared the efficacy of different radiotherapy doses (12 fractions of 24 Gy vs. 2 fractions of 4 Gy) for indolent non-Hodgkin lymphoma, and found that 12 fractions of 24 Gy resulted in better local control.
Article
Oncology
Kyoko Nakamura, Ankur Karmokar, Paul M. Farrington, Neil H. James, Antonio Ramos-Montoya, Susan J. Bickerton, Gareth D. Hughes, Timothy M. Illidge, Elaine B. Cadogan, Barry R. Davies, Simon J. Dovedi, Viia Valge-Archer
Summary: The combination of AZD7648 with radiotherapy induced complete tumor regressions in a significant proportion of mice, dependent on CD8T cells and modulating an anticancer immune response. Immunological consequences included a reduction in T-cell PD-1 expression, increased NK-cell granzyme B expression, and elevated type I IFN signaling.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, Research & Experimental
Nicolas Martinez-Calle, Amy A. Kirkwood, Maxine Lamb, Alex Smith, Jahanzaib Khwaja, Kate Manos, Caroline Shrubsole, Nicola Gray, Katharine Lewis, Ann Tivey, Mark J. Bishton, Eliza Hawkes, Matthew J. Ahearne, Wendy Osborne, Graham P. Collins, Timothy Illidge, Kim M. Linton, Kate Cwynarski, Cathy Burton, Christopher P. Fox
Summary: BV-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). The retrospective analysis showed ALK status remains a strong predictor of outcomes.
ADVANCES IN THERAPY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Tim M. Illidge, Elizabeth Phillips
Summary: The use of 18F-FDG PET CT in lymphoma management has seen significant progress in personalised treatment approaches and the standardisation of PET methods and reporting, including the 5-point Deauville scale. PET has been extensively researched as a predictive imaging biomarker in assessing treatment outcomes, particularly in malignant lymphomas, and has shown success in guiding more personalised risk-adapted approaches.
BRITISH JOURNAL OF RADIOLOGY
(2021)
Article
Oncology
David J. Cutter, Johanna Ramroth, Patricia Diez, Andy Buckle, Georgios Ntentas, Bilyana Popova, Laura Clifton-Hadley, Peter J. Hoskin, Sarah C. Darby, John Radford, Tim Illidge
Summary: This study aims to provide information on the risk of radiation-related cardiovascular disease in early-stage Hodgkin lymphoma patients to help personalize radiotherapy delivery. The predicted excess cardiovascular risk is small for most patients, suggesting that radiotherapy may provide a net benefit.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Vicky Smith, Debayan Mukherjee, Sapna Lunj, Ananya Choudhury, Peter Hoskin, Catharine West, Tim Illidge
Summary: Recent studies have shown that tumor hypoxia is associated with increased PD-L1 expression in bladder cancer. In vitro experiments demonstrated that PD-L1 expression in muscle-invasive bladder cancer cell lines is affected by cell density and is decreased in hypoxic conditions. Furthermore, in silico analyses revealed a positive correlation between hypoxia signature scores and PD-L1 expression in patient-derived bladder cancer tumors.
Article
Hematology
Christopher P. Fox, Matthew J. Ahearne, Ruth Pettengell, Claire Dearden, Dima El-Sharkawi, Shireen Kassam, Lucy Cook, Kate Cwynarski, Tim Illidge, Graham Collins
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Chalid Assaf, Nathalie Waser, Martine Bagot, Mary He, Tina Li, Mehul Dalal, Francois Gavini, Fabrizio Trinchese, Athanasios Zomas, Meredith Little, Nicola Pimpinelli, Pablo L. Ortiz-Romero, Timothy M. Illidge
Summary: This study provides real-world data on the treatment patterns and outcomes of relapsed or refractory CTCL, highlighting the diverse treatment approaches and the lack of consensus in managing this condition.
Article
Oncology
S. Horwitz, O. A. O'Connor, B. Pro, L. Trumper, S. Iyer, R. Advani, N. L. Bartlett, J. H. Christensen, F. Morschhauser, E. Domingo-Domenech, G. Rossi, W. S. Kim, T. Feldman, T. Menne, D. Belada, A. Illes, K. Tobinai, K. Tsukasaki, S-P Yeh, A. Shustov, A. Huettmann, K. J. Savage, S. Yuen, P. L. Zinzani, H. Miao, V Bunn, K. Fenton, M. Fanale, M. Puhlmann, T. Illidge
Summary: In the 5-year update of ECHELON-2, frontline treatment of PTCL patients with A+CHP continues to show clinically meaningful improvements in PFS and OS compared to CHOP, with continued resolution or improvement of peripheral neuropathy.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
James M. Price, Hitesh B. Mistry, Guy Betts, Eleanor J. Cheadle, Lynne Dixon, Kate Garcez, Tim Illidge, Zsuzsanna Iyizoba-Ebozue, Lip Wai Lee, Andrew McPartlin, Robin J. D. Prestwich, Savvas Papageorgiou, Dylan J. Pritchard, Andrew Sykes, Catharine M. West, David J. Thomson
Summary: This study aimed to investigate whether pretreatment absolute lymphocyte count (ALC) predicts the effectiveness of concurrent chemotherapy with radical radiotherapy in patients with oropharyngeal squamous cell carcinoma (OPSCC). The results showed that pretreatment ALC is predictive of overall survival (OS) and predicts the benefit of adding cisplatin chemotherapy to radiotherapy. These findings can help select patients with good prognosis for treatment de-escalation trials.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Vicky Smith, Debayan Mukherjee, Anna Maria Tsakiroglou, Alexander Baker, Hitesh Mistry, Ananya Choudhury, Peter Hoskin, Timothy Illidge, Catharine M. L. West
Summary: Precision medicine is needed for muscle-invasive bladder cancer to improve survival rates. CD8 T cell counts show promise as a predictive biomarker for immune checkpoint inhibitors (ICIs). However, there is currently no biomarker to stratify patients for hypoxia-targeting or immune-targeting therapies.
Article
Biochemistry & Molecular Biology
Vicky Smith, Dave Lee, Mark Reardon, Rekaya Shabbir, Sudhakar Sahoo, Peter Hoskin, Ananya Choudhury, Timothy Illidge, Catharine M. L. West
Summary: Hypoxia and suppressive TME are negative prognostic factors for MIBC. Transcriptomic analyses show that hypoxia increases immune signalling and infiltrates in bladder cancer. This study investigates the relationship between HIF-1 and -2, hypoxia, immune signalling, and infiltrates in MIBC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Urszula M. Cytlak, Douglas P. Dyer, Jamie Honeychurch, Kaye J. Williams, Mark A. Travis, Timothy M. Illidge
Summary: Radiotherapy has both direct cytotoxic effects on tumors and potential immunomodulatory effects on surrounding tissues, leading to chronic inflammation and organ dysfunction. This can impact the quality of life for cancer survivors.
NATURE REVIEWS IMMUNOLOGY
(2022)